Clinical trial
Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer Patients
NCT07924046 is registered in ClinicalTrials.gov with University of Lausanne Hospitals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer Patients
- Lead sponsor
- University of Lausanne Hospitals
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- March 31, 2028
- Enrollment
- 86 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
nmibc, turbt, urinary bladder cancer, vi-rads
Arms
As registered; 1 arm.
-
Multiparametric Magnetic Resonance Imaging
Participants with suspected bladder cancer will undergo multiparametric magnetic resonance imaging before transurethral resection of bladder tumour. Patients requiring repeat resection according to clinical indications will undergo a second magnetic resonance imaging examination approximately 3-4 weeks after the initial resection. Imaging findings will be compared with histopathological results to assess diagnostic performance.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Diagnostic Performance
Diagnostic accuracy metrics (sensitivity, specificity, positive predictive value \[PPV\], and negative predictive value \[NPV\]) of mpMRI performed 3-4 weeks after initial TURBT for detecting residual bladder tumour, using histopathology as the reference standard.
Lead sponsor's other trials
University of Lausanne Hospitals, most recent start first.
+322 more trials See the organization page
Similar trials
Same condition (Non-Muscle Invasive Bladder Neoplasms) and phase, most recent start first.
+45 more trials See the condition page